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Introduction
Adenosine is a purine nucleoside that presents ubiquitously throughout the body and is involved in numerous vital biological functions. [1] Along with its involvement in important physiological processes as a substructure of endogenous molecules such as ATP [2] or RNA, adenosine acts at an extracellular level, where it is the native ligand for adenosine receptors. These adenosine receptors are divided into four subtypes: A1, A2A, A2B, and A3, each belonging to the broader family of G-protein-coupled receptors (GPCRs). [3] Adenosine signalling is widespread throughout mammalian organisms and each class of adenosine receptor possess distinct distributions and control over a broad spectrum of physiological and pathophysiological functions. [4] Several studies have been conducted into the various subclasses of adenosine receptors, mostly relating to the inherent wider biological implications of their stimulation. [4] [5] The A2A adenosine receptors are responsible for the modulation of secondary messenger pathways, in particular the regulation of intracellular cyclic adenosine monophosphate (cAMP) biosynthesis. [6] Upon binding of adenosine to the adenosine A2A receptor, and following its subsequent activation, levels of adenylyl cyclase are enhanced, thus stimulating cAMP production. A2A adenosine receptors are found in numerous regions throughout the body, but they are most notably expressed in the immune cells of the spleen, leukocytes, blood platelets, and in the heart where adenosine is responsible for regulating the vasodilation of the coronary arteries, thus mediating coronary blood flow. Adenosine receptors are also significant in particular regions of the brain including the thymus, striatopallidal GABAergic neurons and the olfactory bulb, where they play an important role in the regulation of glutamate and dopamine release. [1, 7] A2A adenosine receptors have been the subject of increased focus in recent years due to their association with numerous pathogenic, myocardial and neurological diseases. As such, they have become a therapeutic target for treatment of disorders ranging from inflammation, ischemia reperfusion injury, insomnia, infectious diseases, depression to CNS disorders and Parkinson's disease.
[1, [7] [8] Considerable effort has been made to establish structure-activity relationships of adenosine-based ligands with respect to their stimulation of adenosine receptors, and from these studies a general pharmacophore has been established. [9] Predominant approaches to develop A2A adenosine receptor agonists originate through modification of adenosine itself, and from these attempts it has been acknowledged that the adenosine scaffold must be largely maintained as the structural basis for agonist activity (see Figure 1) . Furthermore, modifications to distinct regions of this scaffold can have discrete and significant effects on the binding and selectivity of adenosine analogues. Concerning the A2A adenosine receptor specifically, it has been shown that the 2ʹ-and 3ʹ-hydroxyl groups on the ribose sugar are essential for full agonist activity, although modifications at the C-2 and N-6 positions of the adenine base (which often bring rise to increased metabolic stability), as well as modifications to the 5' position of the ribose ring are tolerated. However, N-6 substitution generally decreases A2A adenosine receptor potency, and in many instances substitution at this position enhances the affinity and selectivity of A1 and A3 receptor binding. [7, 9a] Herein we describe the synthesis of novel C-2 ethynyl adenosines 1 and 2 modified at C-5' of the ribose ring with a fluorodeoxy moiety (see Figure 2 ), along with assessment of their affinities for the human A2A adenosine receptor and their agonist behaviour. The fluorine in these agonists presents an immediate opportunity to develop radiotracers for PET imaging using the fluorine-18 isotope, as the 5'-fluorodeoxyadenosine motif is compatible with the enzymatic introduction of However, the enzyme has been shown to catalyse a transhalogenation reaction using C-2 acetylene substituted 5'-chlorodeoxyadenosine substrates to prepare 18 F-labelled C-2 acetylene substituted 5'-fluorodeoxyadenosines under experimentally benign conditions (buffers at pH 7.8) as illustrated in Scheme 1. [11] This has led to the strategy of tethering PEGylated peptide cargo (R group in Scheme 1)
to permit last step [
18 F]radiolabelling of cancer targeting peptides. [11] [12] A B Scheme 1. Fluorinase-catalysed transhalogenation reactions with C-2 modified 5'-chloro-5'-deoxyadenosine substrates.
This study encompasses a strategy for both the chemical and enzymatic syntheses of 1 and 2, which are derivatives of the adenosine receptor agonists in Figure 1 . [13] As the fluoromethyl group at C-5' of this structural class of agonist had the potential to render them amenable to enzymatic fluorination from their chlorinated precursors using [ 
Results and Discussion

Synthesis
The synthesis of 1 and 2, along with their chlorinated precursors 19 and 24, required an approach involving a Sonogashira coupling reaction between the C-2 iodinated adenosine scaffold and the appropriate functionalised alkyne coupling partner. For this study, 5ʹ-fluoro-5ʹ-deoxy-2-iodoadenosine 13 and 5ʹ-chloro-5ʹ-deoxy-2-iodoadenosine 11 were synthesised using previously reported strategies [12b] as illustrated in Scheme 2. Briefly, 8 was synthesised from guanosine using a two-step procedure first involving the per acetylation of the ribose moiety, followed by chlorination at C-6 of the guanine base using POCl3. 8 was then iodinated at C-2 to afford 9, which was subjected to simultaneous amination and deprotection to give 2-Iodoadenosine 10. With 10 in hand, treatment with thionyl chloride followed by treatment with ammonia in aqueous methanol afforded the 5ʹ-chloro-2-iodinated coupling partner 11. Alternatively, acetonide protection of 11, before fluorination with TsF and TBAF, followed by deprotection with TFA, afforded 13 in good yield.
The formation of alkyne 18 was achieved from commercially available N-Boc-4-piperidinemethanol 14. Introduction of a tosyl group to N-Boc-4-piperidinemethanol 14 afforded 15 which, after flash chromatography, allowed for the insertion of a terminal alkyne using lithium acetylide/ethylenediamine complex in DMSO. Removal of the Boc group gave the free amine 17, which followed by treatment with TEA and methyl chloroformate afforded 18 in good yield. Sonogashira cross-coupling was then performed using an excess of the alkyne 18 over 11 in the presence of a Pd2(dba)3 catalyst, CuI, and trimethylamine, in DMF. The product was subjected to C18 cartridge purification, followed by semi-prep HPLC to afford the coupled product 19 in good yield and high purity. In line with the proposed strategy of using the fluorinase to generate 18 F analogues of these A2A adenosine receptor agonists, 1 was prepared enzymatically by transhalogenation of 19 in good yield as illustrated in Scheme 3 (See supporting Information for full experimental details for preparative transhalogenation). Product 2 was acquired from a similar a strategy commencing with 1-Boc-piperazine 20. Introduction of the acetylene was accomplished using TEA and propargyl bromide, which after purification afforded 21 in very good yield. As before, the methyl carbamate moiety was introduced using successive TFA deprotection of the Boc protected amine, followed by treatment with methyl chloroformate in the presence of an excess of base to afford 23. With 23 in hand Sonogashira cross-coupling was performed using the previously established protocol, with both the 5ʹ-fluoro-5ʹ-deoxy-2-iodoadenosine 13 and 5ʹ-chloro-5ʹ-deoxy-2-iodoadenosine 11 coupling partners as illustrated in Scheme 4. Purification by C18 cartridge followed by semi prep HPLC afforded 2 and 24 in good yields and in high purity Radioligand displacement assays on Hek293 membranes expressing the human A2A receptor With 1 and 2 in hand their relative affinities to the A2A adenosine receptor and any potential agonist activity was evaluated. Radioligand displacement experiments at the human A2A adenosine receptor were performed with a range of concentrations of each potential ligand, in the presence of [ 3 H]-ZM241385. As a reference, CGS21680, a known agonist which possesses a high affinity to the A2A adenosine receptor, [15] was also included in these experiments (Figure 3 ). Subsequent concentrationresponse curves were well behaved, and revealed the affinities of 1 and 2 for the human adenosine A2A receptor to be both in the nanomolar range, with Ki values of 39 nM and 176 nM, respectively. Encouragingly, the affinity of the reference agonist CGS21680 under these conditions was also 39 nM, notably comparable to that of 1 (see also To determine the agonist behavior of 1 and 2 each experiment was repeated in the presence of 1M NaCl. The binding of a sodium ion to the allosteric binding pocket of the human A2A adenosine receptor stabilises the inactive conformation, and this results in an observed reduction in orthosteric binding of the agonists. [16] During these experiments the presence of sodium ion dramatically decreased the affinities of 1 and 2 to (sub)micromolar values (Table 1) , consistent with both compounds acting as agonists of the human A2A adenosine receptor.
[17] Table 1 . Affinities of 1, 2 and the control CGS21680 to the A2A adenosine receptor in the absence and presence of sodium ion. ) in the presence of L-Se-Met (75 μM), potassium fluoride (50 mM) in phosphate buffer, at pH 7.8 (see the Experimental Section and Supporting Information for full experimental details and Figures). In order to monitor the progress of each assay, analytical time course experiments were conducted by removing aliquots from each reaction at specified time points. The enzyme was first removed by heat precipitation, followed by centrifugation, and conversions were determined by HPLC. Both 19 and 24 proved to be very good substrates for fluorinase mediated transhalogenation to generate 1 and 2 respectively (see Figures 4 and 5) . The identities of both fluorinated products were confirmed by both mass spectrometry, and against fully characterised synthetic reference samples. The success of these reactions demonstrates that the methyl piperizine/piperidine-1-carboxylate groups of 19 and 24 do not negatively interfere with the action of the fluorinase enzyme, despite being on a short tether to the 5'-chloro-5ʹ-deoxy-adenosine recognition/substrate motif. This opened up the prospect for direct 'last-step' [ There have been numerous studies probing the substrate specificity of the fluorinase enzyme. To date, these have revealed only a limited tolerance at N-6 and C-2 of the adenine base, [18] or more elaborate additions to the acetylene terminus of elongated PEG chains projecting from C-2. [11] 19 and 24 represent a new class of fluorinase substrate, whereby a more bulker cyclic substituent is incorporated just one methylene unit removed from the C-2 alkyne of the ClDEA motif, thus demonstrating a development in fluorinase substrate specificity. After a 30 min reaction the enzyme was heat denatured and cleanly removed by centrifugation. The clarified supernatant was then purified using semi-preparative HPLC to obtained [ F-labelling methodology provides a novel route for generating a new class of human A2A adenosine receptor targeting PET tracer candidates, while offering the principle advantages of an enzyme mediated synthesis (aqueous and ambient conditions, neutral pH). A common drawback with the development of small molecular weight PET tracers from known agonists is that it often necessitates the addition of a structurally bulky radiolabelled prosthetic or chelating group. The addition of such a group can often perturb the binding and pharmacokinetics of the ligand, and in the case of the human A2A adenosine receptor SAR studies have shown a relatively strict structural scaffold must be maintained when developing adenosine based agonists. This fluorinase mediated strategy allows for smoother transition from the discovery of any new 5'-fluorodeoxyadenosine (FDA) based receptor agonists of this class to the development of its corresponding 
Conclusions
This study demonstrates a new class of A2A adenosine receptor agonist which is designed around a 5'-fluorodeoxy-adenosine (FDA) scaffold. From this class, two novel agonists were synthesized and their affinity and agonist behavior against the human A2A adenosine receptor was determined. The substrate scope of the fluorinase enzyme was further explored and expanded in the fluorinase mediated synthesis of [ 18 F]1, which demonstrated an efficient radiolabeling strategy that avoids the need to sacrifice structural integrity in the development of PET tracers from known agonists. Such a strategy can be applied to future A2A adenosine receptor agonists of this structural class.
Experimental Section
Cold Transhalogenation assay of 19 to 1, and 24 to 2 In a total reaction volume of 1000 μL (in 50 mM phosphate buffer, at pH 7.8), recombinant fluorinase (0.7 mg/mL −1 ) was incubated with 19 (0.1 mM) or 24 (0.2 mM), L-SeMet (0.075 mM) and KF (50 mM) at 37 °C. Samples (50 μL) were periodically removed, the protein precipitated by heating at 95 °C for 5 min, before being clarified by centrifugation (13 000 rpm, 10 min). Samples of the supernatant (40 μL) were removed for analysis by HPLC. HPLC analysis was performed on a Shimadzu Prominence system using a Kinetix 5μm XB-C18 100A (150 mm × 4.6 mm) column and a guard cartridge. Mobile phase: 0.05% TFA in water (solvent A) and 0.05% TFA in MeCN (solvent B); Linear Gradient: 15% solvent B to 95% solvent B over 25 min, 95% for 5 min, and back to 15% B for 10 min to re-equilibrate the column. Flow rate: 1 mL/min at 37 °C for 30 min. After this time the reaction was stopped and the mixture denatured by heating at 95 °C for 5 min, before being clarified by centrifugation (13 000 rpm, corresponding to 16060 g, 5 min). The supernatant was injected into a Shimadzu Prominence HPLC system equipped with a quaternary pump, a degasser, a diode array detector and a radioactivity detector using a Phenomenex Kingsorb C18 (250 × 10.00 mm, 5μ) column and a guard cartridge. Mobile phase: 0.05% TFA in water (solvent A) and 0.05% TFA in MeCN (solvent B); Linear Gradient: 15% solvent B to 38% solvent B over 16 min, 95% for 5 min, and back to 15% B for 10 min to re-equilibrate the column. Flow rate: 5 mL/min −1
. The radioactive fraction corresponding to the reference of [ 18 F]1 was collected, diluted with water (50 mL) and loaded onto a preactivated Waters Oasis HLB® Cartridge (conditioned with 2 mL EtOH, 5 mL water). The cartridge was washed with 20 mL of water and the desired product was collected by eluting with 0.5 mL of ethanol, to give about 7 MBq (3.5 %, decay uncorrected) of >99% pure product of Radioligand displacement assays on Hek293 membranes expressing the human A2A receptor Radioligand displacement experiments were performed using 6 concentrations of competing ligand in the presence of 1.7 nM [ 3 H]ZM241385. At this concentration total radioligand binding did not exceed 10% of that added to prevent ligand depletion. The incubations were performed under standard conditions and in the presence of 1M NaCl to test the effect of NaCl on agonist affinity. Nonspecific binding was determined in the presence of 100 µM NECA (5ʹ-(N-Ethylcarboxamido)adenosine). Membrane aliquots containing 30 µg of protein were incubated in a total volume of 100 µL of assay buffer (25 mM Tris-HCl, pH 7.4) at 25 o C for 2 h to ensure equilibrium was reached.
Incubations were terminated by rapid vacuum filtration to separate the bound and free radioligand through prewetted 96-well GF/B filter plates using a PerkinElmer Filtermate-harvester (Perkin Elmer, Groningen, the Netherlands) after the indicated incubation time. Filters were subsequently washed 12 times with ice-cold wash buffer (25 mM Tris-HCl, pH 7.4). The plates were dried at 55 o C and Microscint TM -20 cocktail (Perkin Elmer, Groningen, The Netherlands) was added. After 3 h the filterbound radioactivity was determined by scintillation spectrometry using a 2450 MicroBeta Microplate Counter (Perkin Elmer, Groningen, The Netherlands).
See Supporting Information for experimental detail on: Compound synthesis, characterisation, large scale enzymatic synthesis of 1, fluorinase overexpression and purification, and HEK293hA2AR cell culture, membrane preparation and data analysis
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